Contra-Indications, Warnings etc.
For animal treatment only. For oral use only. Wash hands
Palatable beige, ovaloid tablets which are scored on both
In man, the combination of ACE inhibitors and NSAIDS
2.5 mg benazepril hydrochloride (Fortekor® 2.5).
can lead to reduced antihypertensive efficacy or impaired
Fortekor 5 and 20:
renal function. Therefore concurrent use of NSAIDS
Ovaloid, biconvex film-coated tablets which are scored
Transient signs of hypotension such as tiredness or
5 mg benazepril hydrochloride (Fortekor® 5).
Marked “CG” on one side and “LV” on the reverse.
Interactions with potassium preserving drugs, like
spironolactone, triamteren or amilorid cannot be ruled
20 mg benazepril hydrochloride (Fortekor® 20).
out. It is recommended to monitor plasma potassium
Marked “CG” on one side and “HP” on the reverse.
levels when using benazepril in combination with a
potassium sparing diuretic. As with other ACE inhibitors,
Fortekor is indicated for the treatment of heart failure in
the use of hypotensive medicinal products or anaesthetics
dogs and chronic renal insufficiency in cats. The active
with a hypotensive effect may add to the anti-hypertensive
ingredient is benazepril. After oral administration, bena-
effect of benazepril. Fortekor is not recommended for
zepril is rapidly absorbed from the gastrointestinal tract
breeding dogs, pregnant or lactating bitches. As is
and hydrolysed into benazeprilat, a highly specific and
routine in cases of renal insufficiency, it is recommended
potent inhibitor of angiotensin converting enzyme (ACE).
to monitor plasma urea and creatinine concentrations.
Fortekor produces significant inhibition of plasma ACE
Do not use in any dog that has evidence of cardiac
activity for more than 24 hours after a single dose in cats
output failure due to aortic stenosis.
and dogs. Inhibition of ACE leads to reduced conversion
of inactive angiotensin I into angiotensin II and therefore
Fortekor may increase plasma creatinine concentrations
reduction in the effects mediated by angiotensin II, in-
at the start of the therapy. This effect is related to the
cluding vasoconstriction of both arteries and veins and
therapeutic effect of the product in reducing blood
retention of sodium and water by the kidney. In dogs with
pressure and therefore is not necessarily a reason to stop
heart failure, Fortekor lowers the blood pressure and
therapy in the absence of other signs. As is routine in
cases of renal insufficiency, it is recommended to monitor
Fortekor leads to a significant extension of the life span of
plasma urea and creatinine concentrations and
dogs with heart failure and also improves clinical signs,
notably reduction in coughing and improvement of the
Fortekor reduced erythrocyte counts in normal cats at
quality of life. In contrast with other ACE inhibitors, bena-
high doses, but this effect was not observed at the
zeprilat is excreted equally by both biliary and urinary
recommended dose during clinical trials in cats with
routes in dogs and primarly via the biliary route in cats
chronic renal insufficiency. Fortekor may increase food
and therefore no adjustment of the dose of Fortekor is
consumption and body weight in cats. The combination
necessary in the treatment of cases with renal insufficien-
of Fortekor and other anti-hypertensive agents
cy. In cats with chronic renal insufficiency, Fortekor redu-ces the protein loss in urine and lowers the systemic and
(e.g. calcium channel blockers, -blockers or diuretics),
intraglomerular blood pressure. Fortekor increases the
anaesthetics or sedatives may lead to additive
appetite, quality of life and the survival time of the cats,
Fortekor is not recommended for breeding cats, pregnantor lactating queens. The safety and efficacy of Fortekor
Dosage and Administration
has not been established in cats below 2.5 kg.
Heart failure in dogs
The recommended dose is 0.25–0.5 mg benazepril
hydrochloride/kg body weight, to be given orally once
Store in a dry place. Do not store above 25 ºC. Each time
an unused half tablet is stored, it should be returned tothe open blister space, inserted back into the cardboard
box and kept in a safe place out of reach of children.
POM – Prescription Only Medicine
Plastic blister packs each containing 14 tablets:
• Individual pack containing 1 blister (Fortekor 5,
• Pack containing 2 blisters (Fortekor 2.5)
No evidence of renal toxicity to Fortekor has been
observed in dogs during clinical trials. The biliary
excretion of benazepril means there is little risk of
bioaccumulation in dogs and cats with impaired renalfunction.
Dispose of used packaging in the household refuse.
Fortekor can be given with or without food. The duration
Unused product should be returned to the veterinary
of treatment is unlimited. The dose may be doubled, still
administered once daily, if judged clinically necessaryand advised by the veterinary surgeon. When the 10 mgdose is required, veterinary surgeons should consideradministering two 5 mg tablets to limit the use of halftablets.
Fortekor may be given in combination with digoxin,
Manufacturer of the medicinal product
diuretics and anti-arrhythmic drugs as necessary.
Novartis Santé Animale SA, 26, rue de la chapelle
Chronic renal insufficiency in cats
The recommended dose is 0.5–1.0 mg benazepril
Marketing Authorisation Numbers in UK
hydrochloride/kg body weight, to be given orally once
Novartis Animal Health UK Limited, New Cambridge
House, Litlington, Nr. Royston, Hertfordshire SG8 0SS
Fortekor can be given with or without food.
The duration of the treatment will be unlimited.
21709 - UK - PP - Fortekor - 163x297 mm - Black
DOKUMENTIERTE PATIENTENAUFKLÄRUNG Basisinformation über die Hautstraffung mittels Radiofrequenz Die erste Sitzung wurde für den ________ geplant. Liebe Patientin, lieber Patient Sie haben sich für die Straffung der Haut mittels eines Radiofrequenzgerätes (RF) entschieden. Vor der ersten Sitzung wird die Ärztin/der Arzt mit Ihnen über diese Behandlung und die Möglichkeite
First-Trimester Use of Selective Serotonin-Reuptake Inhibitors Carol Louik, Sc.D., Angela E. Lin, M.D., Martha M. Werler, Sc.D., Sonia Hernández-Díaz, M.D., Sc.D., Background The risk of birth defects after antenatal exposure to selective serotonin-reuptake From the Slone Epidemiology Center at Boston University (C.L., M.M.W., S.H.-D., inhibitors (SSRIs) remains controversial. A.A.M.), t